Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mobilizing endothelial progenitor cells.

Alexandra Aicher1, Andreas M Zeiher, Stefanie Dimmeler

  • 1Molecular Cardiology, Department of Internal Medicine III, University of Frankfurt, Germany.

Hypertension (Dallas, Tex. : 1979)
|January 19, 2005
PubMed
Summary

Mobilizing endothelial progenitor cells (EPCs) can enhance neovascularization for treating cardiovascular diseases. This review covers various factors like cytokines, growth factors, and drugs that stimulate EPCs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting TMED4 enhances CD8<sup>+</sup> T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.

Science advances·2026
Same author

Independent and Dose-Dependent Contributions of Clonal Hematopoiesis and Mosaic Loss of Y to Incident Heart Failure.

European journal of heart failure·2026
Same author

Geriatric nutritional risk index associated to long-term prognosis and length of hospitalization in the contemporary transcatheter aortic valve replacement era.

Journal of geriatric cardiology : JGC·2026
Same author

RHOV couples EMT-associated plasticity to cytoskeletal execution of invasion and metastasis.

Cell death discovery·2026
Same author

Endothelial ZBTB16: a molecular shield against cardiac aging.

European heart journal·2026
Same author

Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells.

Cardiovascular research·2025

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Cell Biology

Background:

  • Endothelial progenitor cells (EPCs) play a crucial role in neovascularization.
  • Mobilizing endogenous EPCs is a potential therapeutic strategy for ischemic cardiovascular diseases.
  • Enhancing EPCs can promote the repair of damaged blood vessels.

Purpose of the Study:

  • To review the various agents and factors that mobilize endothelial progenitor cells (EPCs) from bone marrow.
  • To explore the therapeutic potential of EPC mobilization for treating ischemic cardiovascular diseases.
  • To consolidate current knowledge on EPC-mobilizing strategies.

Main Methods:

  • Literature review of studies on EPC mobilization.
  • Analysis of the effects of cytokines, growth factors, chemokines, hormones, drugs, and physical activity on EPCs.
  • Synthesis of data regarding the mechanisms of EPC mobilization.

Main Results:

  • Pro-inflammatory cytokines (e.g., G-CSF, GM-CSF) stimulate EPC mobilization.
  • Growth factors (e.g., VEGF, PlGF, EPO, Ang-1) are potent EPC mobilizers.
  • Chemokines (e.g., SDF-1), hormones (e.g., estrogens), and certain drugs (lipid-lowering, anti-diabetic) also enhance EPC levels.
  • Physical activity has been shown to increase circulating EPCs.

Conclusions:

  • Multiple factors, including cytokines, growth factors, chemokines, hormones, medications, and lifestyle choices, can mobilize EPCs.
  • Targeting EPC mobilization offers a promising therapeutic avenue for enhancing neovascularization in cardiovascular disease.
  • Further research is warranted to optimize EPC-mobilizing therapies for clinical application.

Related Experiment Videos